Treatment and Nursing Application of a New Heterocycle Compound on Children Bronchial Pneumonia

Abstract

A fresh heterocycle compound, namely, 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxylic acid (1), was synthesized by employing 1-(4-aminophenyl)-3-morpholino-5, 6-dihydropyridin-2(1H)-one as the raw material through multiple generation routes. The new compound was characterized by infrared spectroscopy, 1H nuclear magnetic resonance, and single-crystal Xray diffraction. The nursing and treatment applications of the compound against children bronchial pneumonia were examined, and the detailed mechanism was simultaneously analyzed. The release of TNF-α and IL-1β into the alveolar lavage fluid was detected with enzyme-linked immunosorbent assay. Additionally, real-time polymerase chain reaction (RT-PCR) was exploited for identifying the NF-κB activation levels in the epithelial cells of respiratory tract mucosa. Results from the atomistic scale by molecular docking simulation suggest that compound 1 has excellent biological activity, and three hydrogen bonds are formed between compound 1 and the receptor.